Vertex Pharma (VRTX) May weekly 400 straddle priced into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vertex (VRTX) PT Raised to $424 at RBC Capital
May 7, 2024 6:21 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Vertex (NASDAQ: VRTX) to $424.00 (from $417.00) while maintaining a Sector Perform rating.
The analyst comments "A solid 1Q optically, with WW CF sales exceeding expectations, though this was driven mainly by ex-U.S.... More
